KR20060034287A - 병용 요법 - Google Patents

병용 요법 Download PDF

Info

Publication number
KR20060034287A
KR20060034287A KR1020067000639A KR20067000639A KR20060034287A KR 20060034287 A KR20060034287 A KR 20060034287A KR 1020067000639 A KR1020067000639 A KR 1020067000639A KR 20067000639 A KR20067000639 A KR 20067000639A KR 20060034287 A KR20060034287 A KR 20060034287A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
azd2171
acceptable salt
effective amount
administering
Prior art date
Application number
KR1020067000639A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 로버트 웨지
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20060034287A publication Critical patent/KR20060034287A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020067000639A 2003-07-10 2004-07-07 병용 요법 KR20060034287A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316123.9A GB0316123D0 (en) 2003-07-10 2003-07-10 Combination therapy
GB0316123.9 2003-07-10

Publications (1)

Publication Number Publication Date
KR20060034287A true KR20060034287A (ko) 2006-04-21

Family

ID=27741905

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067000639A KR20060034287A (ko) 2003-07-10 2004-07-07 병용 요법

Country Status (18)

Country Link
US (1) US20060160775A1 (es)
EP (1) EP1651227B1 (es)
JP (1) JP2007526887A (es)
KR (1) KR20060034287A (es)
CN (1) CN100435799C (es)
AT (1) ATE385798T1 (es)
AU (1) AU2004255023B2 (es)
BR (1) BRPI0412450A (es)
CA (1) CA2531643A1 (es)
DE (1) DE602004011781T2 (es)
ES (1) ES2299841T3 (es)
GB (1) GB0316123D0 (es)
HK (1) HK1089384A1 (es)
IL (1) IL172682A0 (es)
MX (1) MXPA06000413A (es)
NO (1) NO20056171L (es)
WO (1) WO2005004871A1 (es)
ZA (1) ZA200600188B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
NZ549552A (en) * 2004-03-23 2009-12-24 Astrazeneca Ab Combination therapy involving 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (AZD2171) and a platinum anti-tumour agent
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP1901754A2 (en) * 2005-07-06 2008-03-26 AstraZeneca AB Combination therapy of cancer with azd2171 and gemcitabine
US20080306094A1 (en) * 2005-12-22 2008-12-11 Stephen Robert Wedge Combination of Azd2171 and Pemetrexed
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU762615B2 (en) * 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
AU763618B2 (en) * 1999-02-10 2003-07-31 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
NZ534190A (en) * 2000-03-31 2007-05-31 Angiogene Pharm Ltd Divided dose therapies with vascular damaging activity
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy

Also Published As

Publication number Publication date
CN1819830A (zh) 2006-08-16
HK1089384A1 (en) 2006-12-01
NO20056171L (no) 2006-02-07
EP1651227A1 (en) 2006-05-03
AU2004255023A1 (en) 2005-01-20
BRPI0412450A (pt) 2006-09-19
EP1651227B1 (en) 2008-02-13
IL172682A0 (en) 2006-04-10
MXPA06000413A (es) 2006-03-17
CN100435799C (zh) 2008-11-26
CA2531643A1 (en) 2005-01-20
DE602004011781D1 (de) 2008-03-27
ES2299841T3 (es) 2008-06-01
US20060160775A1 (en) 2006-07-20
DE602004011781T2 (de) 2009-02-19
ZA200600188B (en) 2007-04-25
JP2007526887A (ja) 2007-09-20
WO2005004871A1 (en) 2005-01-20
GB0316123D0 (en) 2003-08-13
ATE385798T1 (de) 2008-03-15
AU2004255023B2 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
AU2004255022B2 (en) Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
EP1971338B1 (en) Combination of zd6474 and pemetrexed
KR20070072543A (ko) Ｚｄ6474 및 이마티닙을 포함하는 병합법
JP2008514576A (ja) Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
EP1965801B1 (en) Combination of azd2171 and pemetrexed
JP2010504949A (ja) Ｚｄ６４７４とベバシズマブの癌療法のための組合せ
EP1729808B1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11
EP1729807B1 (en) Combination therapy with azd-2171
JP2007530517A (ja) 組合せ療法
US20090176731A1 (en) Combination therapy of cancer with azd2171 and gemcitabine
EP1651227B1 (en) Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
ZA200600186B (en) Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of deseases associated with angiogenesis and/or increased vascular permeability

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application